secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001564590-22-028771
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q2 2022 revenue rises to $46M, net loss widens to $7M; 4 new program starts
--------------------------------------------------------------------------------

- Total revenue $45.9M, up 66% from $27.6M in Q2 2021; royalties from bebtelovimab contributed $33.2M.
- Net loss $6.8M ($0.02/share) vs loss $2.3M ($0.01/share) in prior year, driven by higher R&D and G&A investments.
- Added 4 program starts in Q2, cumulative 88 (+47% YoY); total programs under contract 164 (+19% YoY).
- Six molecules cumulatively advanced to clinic, up from 4 at Q2 2021.
- Cash & marketable securities $1.022B; R&D expenses $26.7M (+78% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022028771/0001564590-22-028771-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459022028771/abcl-8k_20220809.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-028771

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer